Protocol Ledger

NCT04628026 · Phase III · RECRUITING

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Interventional Phase III clinical trial protocol NCT04628026 sponsored by University of Ulm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-13 Enrollment: 650 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04628026
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)650 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04628026
Protocol FieldVerified Registry Value
NCT IdentifierNCT04628026
Consolidated Lead SponsorUniversity of Ulm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment650 participants (ESTIMATED)
Registered Start Date2022-09-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04628026
Hospital Research SiteLocationSite Profile
Tampere University HospitalTampere, FinlandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI